Introduction to Refractory Multiple
Sentence Examples
Discover more insights into Refractory Multiple
Keywords frequently search together with Refractory Multiple
Narrow sentence examples with built-in keyword filters
Refractory Multiple sentence examples within chimeric antigen receptor
More recently, T cell-based immunotherapeutics (including chimeric antigen receptor T-cell therapies and bispecific T-cell engagers) have shown dramatic clinical benefits in patients with relapsed or refractory multiple myeloma.
More recently, T cell-based immunotherapeutics (including chimeric antigen receptor T-cell therapies and bispecific T-cell engagers) have shown dramatic clinical benefits in patients with relapsed or refractory multiple myeloma.
Full Text
Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM).
Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM).
Full Text
Refractory Multiple sentence examples within cell maturation antigen
B-cell maturation antigen-targeted chimeric antigen receptor T cell therapy (BCMA CAR-T) is an effective treatment for relapsed refractory multiple myeloma (RRMM).
B-cell maturation antigen-targeted chimeric antigen receptor T cell therapy (BCMA CAR-T) is an effective treatment for relapsed refractory multiple myeloma (RRMM).
Full Text
BACKGROUND
There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target.
BACKGROUND
There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target.
Full Text
Refractory Multiple sentence examples within progression free survival
Background Phase IIb clinical trial with isatuximab (Isa)-lenalidomide (Len)-dexamethasone (Dex) showed an improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (RRMM), but the efficacy varied by patient.
Background Phase IIb clinical trial with isatuximab (Isa)-lenalidomide (Len)-dexamethasone (Dex) showed an improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (RRMM), but the efficacy varied by patient.
Full Text
PURPOSE
The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd in patients with relapsed or refractory multiple myeloma.
PURPOSE
The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd in patients with relapsed or refractory multiple myeloma.
Full Text
Learn more from Refractory Multiple
Refractory Multiple sentence examples within belantamab mafodotin belamaf
e20014 Background: Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of relapsed/refractory multiple myeloma on July 2019 and August 2020 respectively.
e20014 Background: Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of relapsed/refractory multiple myeloma on July 2019 and August 2020 respectively.
Full Text
3248 Patient-Reported Experiences During and Following Treatment With Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study Laurie Eliason, MPH, Julia Correll, MPH, Mona Martin, MPA, Anna Cardellino, MPH, Joanna Opalinska, MD, Trisha Piontek, BSN, Boris Gorsh, PharmD, Sandhya Sapra, PhD, and Rakesh Popat Visit https://doi.
3248 Patient-Reported Experiences During and Following Treatment With Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study Laurie Eliason, MPH, Julia Correll, MPH, Mona Martin, MPA, Anna Cardellino, MPH, Joanna Opalinska, MD, Trisha Piontek, BSN, Boris Gorsh, PharmD, Sandhya Sapra, PhD, and Rakesh Popat Visit https://doi.
Full Text
Refractory Multiple sentence examples within heavily pretreated relapsed
Methods: From October 2019 to July 2020, 19 heavily pretreated Relapsed/Refractory Multiple Myeloma (RRMM) pts (age 27-71) with a median of 5 prior lines (range 2-9) received a single infusion of GC012F.
Methods: From October 2019 to July 2020, 19 heavily pretreated Relapsed/Refractory Multiple Myeloma (RRMM) pts (age 27-71) with a median of 5 prior lines (range 2-9) received a single infusion of GC012F.
Full Text
Recently, advances in immunotherapy have revolutionized standard-of-care therapies and provided therapeutic options for patients with heavily pretreated, relapsed refractory multiple myeloma.
Recently, advances in immunotherapy have revolutionized standard-of-care therapies and provided therapeutic options for patients with heavily pretreated, relapsed refractory multiple myeloma.
Full Text
Refractory Multiple sentence examples within autologous stem cell
Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM).
Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM).
Full Text
Conclusions Second autologous stem cell transplant is an effective option for relapsed and refractory multiple myeloma.
Conclusions Second autologous stem cell transplant is an effective option for relapsed and refractory multiple myeloma.
Full Text
Refractory Multiple sentence examples within newly diagnosed multiple
Dear Editor, Daratumumab (Dara)-combination regimens have shown promising outcomes for patients with newly diagnosed multiple myeloma (NDMM) or relapsed and refractory multiple myeloma (RRMM).
Dear Editor, Daratumumab (Dara)-combination regimens have shown promising outcomes for patients with newly diagnosed multiple myeloma (NDMM) or relapsed and refractory multiple myeloma (RRMM).
Full Text
Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory multiple myeloma.
Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory multiple myeloma.
Full Text
Refractory Multiple sentence examples within year old man
Superficial keratopathy: 2 case reports In a report, a 56-year-old man and a 77-year-old man was described who developed superficial keratopathy during treatment with belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM).
Superficial keratopathy: 2 case reports In a report, a 56-year-old man and a 77-year-old man was described who developed superficial keratopathy during treatment with belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM).
Full Text
Myelodysplasia: case report A 71-year-old man developed myelodysplasia during treatment with daratumumab, pomalidomide and dexamethasone for refractory multiple myeloma.
Myelodysplasia: case report A 71-year-old man developed myelodysplasia during treatment with daratumumab, pomalidomide and dexamethasone for refractory multiple myeloma.
Full Text
Refractory Multiple sentence examples within phase 3 trial
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Full Text
METHODS
In this ongoing, open-label, randomised, phase 3 trial (APOLLO) done at 48 academic centres and hospitals across 12 European countries, eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma with measurable disease, had an Eastern Cooperative Oncology Group performance status of 0-2, had at least one previous line of therapy, including lenalidomide and a proteasome inhibitor, had a partial response or better to one or more previous lines of antimyeloma therapy, and were refractory to lenalidomide if only one previous line of therapy was received.
METHODS
In this ongoing, open-label, randomised, phase 3 trial (APOLLO) done at 48 academic centres and hospitals across 12 European countries, eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma with measurable disease, had an Eastern Cooperative Oncology Group performance status of 0-2, had at least one previous line of therapy, including lenalidomide and a proteasome inhibitor, had a partial response or better to one or more previous lines of antimyeloma therapy, and were refractory to lenalidomide if only one previous line of therapy was received.
Full Text
Refractory Multiple sentence examples within irreversible proteasome inhibitor
Carfilzomib (Cfz), an irreversible proteasome inhibitor, is a first line antineoplastic agent indicated for relapsed/refractory multiple myeloma, with its clinical use being hampered by cardiovascular adverse effects.
Carfilzomib (Cfz), an irreversible proteasome inhibitor, is a first line antineoplastic agent indicated for relapsed/refractory multiple myeloma, with its clinical use being hampered by cardiovascular adverse effects.
Full Text
Carfilzomib is an irreversible proteasome inhibitor (PI), first approved in 2012 for treatment of relapsed refractory multiple myeloma (RRMM).
Carfilzomib is an irreversible proteasome inhibitor (PI), first approved in 2012 for treatment of relapsed refractory multiple myeloma (RRMM).
Full Text
Refractory Multiple sentence examples within agent belantamab mafodotin
Single-agent belantamab mafodotin (belamaf; BLENREP) demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma and ≥ 3 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody (DREAMM-2; NCT03525678).
Single-agent belantamab mafodotin (belamaf; BLENREP) demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma and ≥ 3 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody (DREAMM-2; NCT03525678).
Full Text
gov identifier NCT03525678), single-agent belantamab mafodotin (belamaf) was approved for patients with relapsed or refractory multiple myeloma (RRMM) who received ≥4 prior therapies, including anti-CD38 therapy.
gov identifier NCT03525678), single-agent belantamab mafodotin (belamaf) was approved for patients with relapsed or refractory multiple myeloma (RRMM) who received ≥4 prior therapies, including anti-CD38 therapy.
Full Text
Refractory Multiple sentence examples within year old woman
We present the case of a 67-year-old woman with meningeal carcinomatosis who was treated with chemotherapy for refractory multiple myeloma, and was in remission.
We present the case of a 67-year-old woman with meningeal carcinomatosis who was treated with chemotherapy for refractory multiple myeloma, and was in remission.
Full Text
We present a case of a 61-year-old woman with relapse/refractory multiple myeloma post-autologous peripheral blood stem cell transplantation who presented with recurrent febrile episodes and infection.
We present a case of a 61-year-old woman with relapse/refractory multiple myeloma post-autologous peripheral blood stem cell transplantation who presented with recurrent febrile episodes and infection.
Full Text
Refractory Multiple sentence examples within autoleucel cilta cel
Registrational trials for ciltacabtagene autoleucel [cilta-cel]) and idecabtagene vicleucel [ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR).
Registrational trials for ciltacabtagene autoleucel [cilta-cel]) and idecabtagene vicleucel [ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR).
Full Text
Objective This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300–460 × 106 CAR-positive T-cells for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.
Objective This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300–460 × 106 CAR-positive T-cells for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.
Full Text
Refractory Multiple sentence examples within low dose dexamethasone
The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece.
The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece.
Full Text
Selinexor in combination with low dose dexamethasone is approved for relapsed/refractory multiple myeloma.
Selinexor in combination with low dose dexamethasone is approved for relapsed/refractory multiple myeloma.
Full Text
Refractory Multiple sentence examples within second generation proteasome
We have used a modified regimen incorporating the second-generation proteasome inhibitor carfilzomib (carfilzomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide [KD-PACE]) instead of bortezomib for relapsed/refractory multiple myeloma.
We have used a modified regimen incorporating the second-generation proteasome inhibitor carfilzomib (carfilzomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide [KD-PACE]) instead of bortezomib for relapsed/refractory multiple myeloma.
Full Text
The second-generation proteasome inhibitor carfilzomib produces superior outcomes in relapsed or refractory multiple myeloma (MM).
The second-generation proteasome inhibitor carfilzomib produces superior outcomes in relapsed or refractory multiple myeloma (MM).
Full Text
Refractory Multiple sentence examples within stem cell transplantation
Case presentation We report an unusual case of EF in a 46-year-old Caucasian male patient who had received an allogenic hematopoietic stem cell transplantation in the context of relapsed/refractory multiple myeloma.
Case presentation We report an unusual case of EF in a 46-year-old Caucasian male patient who had received an allogenic hematopoietic stem cell transplantation in the context of relapsed/refractory multiple myeloma.
Full Text
Although elotuzumab (ELO) is associated with improved outcomes in patients with relapsed/refractory multiple myeloma (MM), no data are available for the usage of ELO following allogeneic stem cell transplantation (allo-SCT).
Although elotuzumab (ELO) is associated with improved outcomes in patients with relapsed/refractory multiple myeloma (MM), no data are available for the usage of ELO following allogeneic stem cell transplantation (allo-SCT).
Full Text
Refractory Multiple sentence examples within ixazomib lenalidomide dexamethasone
Objective: To evaluate the efficacy and safety profile of ixazomib/lenalidomide/dexamethasone (IRd) in Chinese patients with relapsed/refractory multiple myeloma (MM).
Objective: To evaluate the efficacy and safety profile of ixazomib/lenalidomide/dexamethasone (IRd) in Chinese patients with relapsed/refractory multiple myeloma (MM).
Full Text
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice.
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice.
Full Text
Refractory Multiple sentence examples within triple class exposed
Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care.
Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care.
Full Text
Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients.
Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients.
Full Text
Refractory Multiple sentence examples within vicleucel ide cel
BACKGROUND
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.
BACKGROUND
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.
Full Text
Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial.
Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial.
Full Text
Refractory Multiple sentence examples within proteasome inhibitor carfilzomib
The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed MM as well.
The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed MM as well.
Full Text
Refractory Multiple sentence examples within Relapsed Refractory Multiple
B-cell maturation antigen-targeted chimeric antigen receptor T cell therapy (BCMA CAR-T) is an effective treatment for relapsed refractory multiple myeloma (RRMM).
B-cell maturation antigen-targeted chimeric antigen receptor T cell therapy (BCMA CAR-T) is an effective treatment for relapsed refractory multiple myeloma (RRMM).
Full Text
The combination of pomalidomide/dexamethasone with either daratumumab or isatuximab is FDA approved for relapsed refractory multiple myeloma (RRMM) based on randomized phase III trial data.
The combination of pomalidomide/dexamethasone with either daratumumab or isatuximab is FDA approved for relapsed refractory multiple myeloma (RRMM) based on randomized phase III trial data.
Full Text
Refractory Multiple sentence examples within Clas Refractory Multiple
Encouragingly, there have been three recent FDA approvals for triple-class refractory multiple myeloma, and there is promising ongoing development of additional agents with varying novel mechanisms of action.
Encouragingly, there have been three recent FDA approvals for triple-class refractory multiple myeloma, and there is promising ongoing development of additional agents with varying novel mechanisms of action.
Full Text
Refractory Multiple sentence examples within Relapse Refractory Multiple
Purpose: The purpose of this study was to compare the measures of efficacy as assessed with estimates of the Overall Response Rate (ORR) or Overall Survival (OS) obtained in RCT and SC studies that evaluate the same treatments for Relapse Refractory Multiple Myeloma (RRMM).
Purpose: The purpose of this study was to compare the measures of efficacy as assessed with estimates of the Overall Response Rate (ORR) or Overall Survival (OS) obtained in RCT and SC studies that evaluate the same treatments for Relapse Refractory Multiple Myeloma (RRMM).
Full Text
Registrational trials for ciltacabtagene autoleucel [cilta-cel]) and idecabtagene vicleucel [ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR).
Registrational trials for ciltacabtagene autoleucel [cilta-cel]) and idecabtagene vicleucel [ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR).
Full Text
Refractory Multiple sentence examples within refractory multiple myeloma
RW data on the role of novel agents and their combinations among patients with relapsed/refractory multiple myeloma have confirmed the efficacy of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
RW data on the role of novel agents and their combinations among patients with relapsed/refractory multiple myeloma have confirmed the efficacy of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
Full Text
CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM).
CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM).
Full Text
Refractory Multiple sentence examples within refractory multiple sclerosi
More Refractory Multiple sentence examples
10.1016/j.clml.2021.01.018
RW data on the role of novel agents and their combinations among patients with relapsed/refractory multiple myeloma have confirmed the efficacy of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
RW data on the role of novel agents and their combinations among patients with relapsed/refractory multiple myeloma have confirmed the efficacy of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
Full Text
More Refractory Multiple sentence examples
10.1080/10428194.2021.1941927
CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM).
CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM).
Full Text
More Refractory Multiple sentence examples
10.1002/ajh.26096
Modified HyperCVAD versus Bortezomib-HyperCAD in patients with relapsed/refractory multiple myeloma.
Modified HyperCVAD versus Bortezomib-HyperCAD in patients with relapsed/refractory multiple myeloma.
Full Text
More Refractory Multiple sentence examples
10.1007/s00277-021-04522-y
Over the past decade, several drugs have been approved for the treatment of relapsed or refractory multiple myeloma (RRMM).
Over the past decade, several drugs have been approved for the treatment of relapsed or refractory multiple myeloma (RRMM).
Full Text
More Refractory Multiple sentence examples
10.1556/650.2021.32179
The first oral proteasome inhibitor ixazomib in combination with lenalidomide-dexamethasone is a tolerable, orally administered regime, which has become available for Hungarian relapsed, refractory multiple myeloma patients from April 2015 in the Named Patient Program.
The first oral proteasome inhibitor ixazomib in combination with lenalidomide-dexamethasone is a tolerable, orally administered regime, which has become available for Hungarian relapsed, refractory multiple myeloma patients from April 2015 in the Named Patient Program.
Full Text
More Refractory Multiple sentence examples
10.3389/fonc.2021.597453
Purpose Although pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined.
Purpose Although pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined.
Full Text
More Refractory Multiple sentence examples
10.12998/wjcc.v9.i5.1175
B-cell lymphoma-2 inhibitor venetoclax is usually used for relapsed/refractory multiple myeloma (RRMM) with t(11;14).
B-cell lymphoma-2 inhibitor venetoclax is usually used for relapsed/refractory multiple myeloma (RRMM) with t(11;14).
Full Text
More Refractory Multiple sentence examples
10.1038/s41375-021-01262-w
gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma patients.
gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma patients.
Full Text
More Refractory Multiple sentence examples
10.1200/JCO.21.00443
PURPOSE
Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation.
PURPOSE
Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation.
Full Text
More Refractory Multiple sentence examples
10.3390/cancers13205036
Simple Summary The treatment of patients with relapsed/refractory multiple myeloma has advanced considerably in recent years, irrespective of whether they are younger or older patients.
Simple Summary The treatment of patients with relapsed/refractory multiple myeloma has advanced considerably in recent years, irrespective of whether they are younger or older patients.
Full Text
More Refractory Multiple sentence examples
10.7150/ijms.46811
For relapsed/refractory multiple myeloma (RRMM), preclinical evaluations of CAR-T therapy have shown promising efficacy, thus various active clinical trials are under way.
For relapsed/refractory multiple myeloma (RRMM), preclinical evaluations of CAR-T therapy have shown promising efficacy, thus various active clinical trials are under way.
Full Text
More Refractory Multiple sentence examples
10.3389/fonc.2021.643490
Citation: Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F and Gentile M (2021) Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.
Citation: Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F and Gentile M (2021) Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.
Full Text
More Refractory Multiple sentence examples
10.1111/1346-8138.15946
Dear Editor, A 34yearold Japanese woman was referred to our clinic with complaints of a 15year history of recurrent and refractory multiple pustules and cystic lesions.
Dear Editor, A 34yearold Japanese woman was referred to our clinic with complaints of a 15year history of recurrent and refractory multiple pustules and cystic lesions.
Full Text
More Refractory Multiple sentence examples
10.1158/1538-7445.AM2021-1372
Model based approach to evaluate Isatuximab (Isa) monthly dosing regimen in relapsed/refractory multiple myeloma (RRMM) [abstract].
Model based approach to evaluate Isatuximab (Isa) monthly dosing regimen in relapsed/refractory multiple myeloma (RRMM) [abstract].
Full Text
More Refractory Multiple sentence examples
10.3390/cancers13071527
The peptide–drug conjugate melflufen was particularly active towards plasma cells from relapsed/refractory multiple myeloma patients.
The peptide–drug conjugate melflufen was particularly active towards plasma cells from relapsed/refractory multiple myeloma patients.
Full Text
More Refractory Multiple sentence examples
10.1016/j.clml.2021.02.004
INTRODUCTION
Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide.
INTRODUCTION
Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide.
Full Text
More Refractory Multiple sentence examples
10.17749/2070-4909/farmakoekonomika.2021.098
The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured remains open.
The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured remains open.
Full Text
More Refractory Multiple sentence examples
10.1182/bloodadvances.2019001059
In the phase 3 ENDEAVOR study, carfilzomib-dexamethasone (Kd) improved survival over bortezomib-dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM), regardless of baseline renal function.
In the phase 3 ENDEAVOR study, carfilzomib-dexamethasone (Kd) improved survival over bortezomib-dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM), regardless of baseline renal function.
Full Text
More Refractory Multiple sentence examples
10.1002/jha2.190
Here, we present a case of a patient that suffered from relapsed/refractory multiple myeloma, a hematologic neoplasm characterized by clonal proliferation of malignant plasma cells in the bone marrow.
Here, we present a case of a patient that suffered from relapsed/refractory multiple myeloma, a hematologic neoplasm characterized by clonal proliferation of malignant plasma cells in the bone marrow.
Full Text
More Refractory Multiple sentence examples
10.1080/10428194.2021.1876864
We report results of a phase-1 study evaluating the safety and anti-cancer activity of the small molecule insulin-like growth factor-1 receptor (IGF-1R) inhibitor, linsitinib combined with bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
We report results of a phase-1 study evaluating the safety and anti-cancer activity of the small molecule insulin-like growth factor-1 receptor (IGF-1R) inhibitor, linsitinib combined with bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Full Text
More Refractory Multiple sentence examples
10.21203/rs.3.rs-593228/v1
Case presentation Here we report a patient with refractory multiple recurrent trigeminal neuralgia, in which we accordingly found that an increase in facial pain trigger points and a rapid movement of the upper limb extremity could trigger an onset of trigeminal neuralgia.
Case presentation Here we report a patient with refractory multiple recurrent trigeminal neuralgia, in which we accordingly found that an increase in facial pain trigger points and a rapid movement of the upper limb extremity could trigger an onset of trigeminal neuralgia.
Full Text
More Refractory Multiple sentence examples
10.3760/cma.j.issn.0253-2727.2021.01.006
Objective: To investigate the efficacy and safety of daratumumab in relapsed and refractory multiple myeloma (RRMM).
Objective: To investigate the efficacy and safety of daratumumab in relapsed and refractory multiple myeloma (RRMM).
Full Text
More Refractory Multiple sentence examples
10.1016/j.msard.2021.103168
INTRODUCTION
Therapeutic plasma exchange (TPE) is considered a treatment option for steroid-refractory multiple sclerosis (MS) relapses.
INTRODUCTION
Therapeutic plasma exchange (TPE) is considered a treatment option for steroid-refractory multiple sclerosis (MS) relapses.
Full Text
More Refractory Multiple sentence examples
10.1016/j.clml.2021.06.020
Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance.
Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance.
Full Text
More Refractory Multiple sentence examples
10.1016/J.ACTAMAT.2021.117233
Refractory multiple principal elemental alloys (MPEAs) hold great promise for structural materials in future nuclear energy systems.
Refractory multiple principal elemental alloys (MPEAs) hold great promise for structural materials in future nuclear energy systems.
Full Text
More Refractory Multiple sentence examples
10.3390/cancers13205057
Simple Summary The management of cardiovascular adverse events in patients with relapsed/refractory multiple myeloma undergoing treatment with carfilzomib can be challenging.
Simple Summary The management of cardiovascular adverse events in patients with relapsed/refractory multiple myeloma undergoing treatment with carfilzomib can be challenging.
Full Text
More Refractory Multiple sentence examples
10.1007/s40278-021-94487-x
The patients had been receiving treatment with thalidomide (1 patient) for refractory multiple myeloma, and amiodarone (2 patients) and phenytoin (1 patient) for unspecified indications.
The patients had been receiving treatment with thalidomide (1 patient) for refractory multiple myeloma, and amiodarone (2 patients) and phenytoin (1 patient) for unspecified indications.
Full Text
More Refractory Multiple sentence examples
10.1200/JCO.2021.39.15_SUPPL.E20039
However, due to the increased relapse incidence, multiple different combination therapies are under study to treat relapsed and refractory multiple myeloma (RRMM).
However, due to the increased relapse incidence, multiple different combination therapies are under study to treat relapsed and refractory multiple myeloma (RRMM).
Full Text
More Refractory Multiple sentence examples
10.1111/bjh.17497
Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Full Text
More Refractory Multiple sentence examples
10.1158/2643-3230.BCD-21-0073
BCMA/CD3ε-targeted bispecific antibody (BsAb) therapy represents a promising T cell-redirecting immunotherapy to treat relapsed and refractory multiple myeloma.
BCMA/CD3ε-targeted bispecific antibody (BsAb) therapy represents a promising T cell-redirecting immunotherapy to treat relapsed and refractory multiple myeloma.
Full Text
More Refractory Multiple sentence examples
10.1080/17474086.2021.1886073
ABSTRACT Objectives We compared the efficacy of lenalidomide-dexamethasone (Rd) based treatments for relapsed/refractory multiple myeloma patients (pts), in a real-world setting.
ABSTRACT Objectives We compared the efficacy of lenalidomide-dexamethasone (Rd) based treatments for relapsed/refractory multiple myeloma patients (pts), in a real-world setting.
Full Text
More Refractory Multiple sentence examples
10.1080/13696998.2020.1867469
AIMS
To assess the real-world healthcare resource utilization (HRU) and costs associated with different proteasome inhibitors (PIs) for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM) in Germany.
AIMS
To assess the real-world healthcare resource utilization (HRU) and costs associated with different proteasome inhibitors (PIs) for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM) in Germany.
Full Text
More Refractory Multiple sentence examples
10.3390/cancers13174320
Treatment options for relapsed/refractory multiple myeloma (RRMM) have largely increased in the last decades.
Treatment options for relapsed/refractory multiple myeloma (RRMM) have largely increased in the last decades.
Full Text
More Refractory Multiple sentence examples
10.2147/OTT.S317570
Carfilzomib (CFZ) is a proteasome inhibitor currently approved for the treatment of relapsed and refractory multiple myeloma (RRMM).
Carfilzomib (CFZ) is a proteasome inhibitor currently approved for the treatment of relapsed and refractory multiple myeloma (RRMM).
Full Text
More Refractory Multiple sentence examples
10.1136/EJHPHARM-2021-EAHPCONF.104
Background and importance Patients with multiple relapses and/ or refractory multiple myeloma are difficult to manage as the therapeutic options become limited and the response to chemotherapy is often short lived.
Background and importance Patients with multiple relapses and/ or refractory multiple myeloma are difficult to manage as the therapeutic options become limited and the response to chemotherapy is often short lived.
Full Text
More Refractory Multiple sentence examples
10.1007/s00277-021-04534-8
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape.
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape.
Full Text
More Refractory Multiple sentence examples
10.1080/16078454.2021.1965737
Daratumumab (dara) with immunomodulatory agents (IMiD) and dexamethasone (dex) was proven highly effective in relapsed or refractory multiple myeloma (RRMM) in randomized controlled trials.
Daratumumab (dara) with immunomodulatory agents (IMiD) and dexamethasone (dex) was proven highly effective in relapsed or refractory multiple myeloma (RRMM) in randomized controlled trials.
Full Text
More Refractory Multiple sentence examples
10.1016/S0140-6736(21)00592-4
BACKGROUND
Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma.
BACKGROUND
Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma.
Full Text
More Refractory Multiple sentence examples
10.1186/s12885-020-07732-1
Background We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice.
Background We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice.
Full Text
More Refractory Multiple sentence examples
10.21203/rs.3.rs-818673/v1
Purpose: This study aimed to better understand the patient perspective on relapsed and/or refractory multiple myeloma (RRMM) treatment.
Purpose: This study aimed to better understand the patient perspective on relapsed and/or refractory multiple myeloma (RRMM) treatment.
Full Text
More Refractory Multiple sentence examples
10.1111/bjh.17413
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Full Text
More Refractory Multiple sentence examples
10.1007/s12288-021-01461-6
Carfilzomib is a second-in class Proteosome Inhibitor and has been approved for Relapsed/Refractory Multiple Myeloma (RRMM).
Carfilzomib is a second-in class Proteosome Inhibitor and has been approved for Relapsed/Refractory Multiple Myeloma (RRMM).
Full Text
More Refractory Multiple sentence examples
10.1016/j.clml.2021.06.003
gov were reviewed and studies mentioning CAR T and studying relapsed/refractory multiple myeloma (R/R MM) were included.
gov were reviewed and studies mentioning CAR T and studying relapsed/refractory multiple myeloma (R/R MM) were included.
Full Text
More Refractory Multiple sentence examples
10.1177/2040620721989578
We report a case of relapsed/refractory multiple myeloma (RRMM)-transformed PCL successfully treated with daratumumab.
We report a case of relapsed/refractory multiple myeloma (RRMM)-transformed PCL successfully treated with daratumumab.
Full Text
More Refractory Multiple sentence examples
10.3390/curroncol28010063
In November 2017, the FDA designated belamaf as a breakthrough therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
In November 2017, the FDA designated belamaf as a breakthrough therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Full Text
More Refractory Multiple sentence examples
10.3390/cancers13205154
The present introductory article of the Special Issue on “Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond” summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies.
The present introductory article of the Special Issue on “Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond” summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies.
Full Text
More Refractory Multiple sentence examples
10.1177/1078155221995532
INTRODUCTION
Real-world evidence on later line treatment of relapsed/refractory multiple myeloma (RRMM) is sparse.
INTRODUCTION
Real-world evidence on later line treatment of relapsed/refractory multiple myeloma (RRMM) is sparse.
Full Text
More Refractory Multiple sentence examples
10.1177/20406207211027463
Aims: This study quantifies the value of survival gains attributable to novel treatments approved since 2003 for United States (US) patients with relapsed/refractory multiple myeloma (RRMM).
Aims: This study quantifies the value of survival gains attributable to novel treatments approved since 2003 for United States (US) patients with relapsed/refractory multiple myeloma (RRMM).
Full Text
More Refractory Multiple sentence examples
10.11406/rinketsu.62.1149
Multiple myeloma has been known as an incurable disease; however, since the approval of bortezomib in Japan in 2006 as the treatment for relapsed and refractory multiple myeloma, novel agents such as immunomodulatory drugs (IMIDs) and antibodies have been introduced one after another.
Multiple myeloma has been known as an incurable disease; however, since the approval of bortezomib in Japan in 2006 as the treatment for relapsed and refractory multiple myeloma, novel agents such as immunomodulatory drugs (IMIDs) and antibodies have been introduced one after another.
Full Text
More Refractory Multiple sentence examples
10.1200/JCO.2021.39.15_SUPPL.8021
Methods: 50 patients with relapsed/refractory multiple myeloma (RRMM) underwent ASCT using HDLEN+HDM conditioning.
Methods: 50 patients with relapsed/refractory multiple myeloma (RRMM) underwent ASCT using HDLEN+HDM conditioning.
Full Text
Learn more from Refractory Multiple
Keywords related to Refractory
Refractory Hypoglycaemia
Refractory Gerd
Refractory Congestive
Refractory Autoimmune
Refractory Seizures
Refractory Neurogenic
Refractory Breathlessness
Refractory Corrosion
Refractory Relapsed Diffuse
Refractory Material
Refractory Neuropathic
Refractory Intracranial
Refractory Macular
Refractory Symptoms
Refractory Epilepsies
Refractory Classic
Refractory Constipation
Refractory Ceramics
Refractory Obsessive Compulsive
Refractory Chylothorax
Refractory Migraine
Refractory Metals
Refractory Black
Refractory Hypoxia
Refractory Psoriatic
Refractory Organics
Refractory Pruritus
Refractory Cytomegalovirus
Refractory Multi Principal
Refractory Recurrent
Refractory Overactive
Refractory Primary
Refractory Colorectal
Refractory Wilms
Refractory Focal
Refractory Atrial
Refractory B
Refractory Ulcerative
Refractory Infection
Refractory Major
Refractory Relapsed Multiple
Refractory Mutation
Refractory Castable
Refractory Melasma
Refractory Cardiogenic
Refractory Functional
Refractory Heart
Refractory Allergic
Refractory Concretes
Refractory Urgency
Explore More
Keywords related to Multiple
Cortical Multiple
Comparative Multiple
Eligible Multiple
Randomized Multiple
Prevent Multiple
Rare Multiple
Human Multiple
Electric Multiple
Across Multiple
Inhibiting Multiple
Comparing Multiple
Improving Multiple
Theory Multiple
Encodes Multiple
Algan Multiple
Students Multiple
Random Multiple
Stage Multiple
Optical Multiple
Four Tier Multiple
Orchestrating Multiple
Affects Multiple
Grant Free Multiple
Non Secretory Multiple
Traumatic Multiple
Moderated Multiple
Switching Multiple
Elucidating Multiple
Structure Multiple
Accessing Multiple
Division Multiple
Beyond Multiple
Resistant Multiple
Requires Multiple
Selling Multiple
Effect Multiple
Exploiting Multiple
Frequency Division Multiple
Activates Multiple
Reveals Multiple
Addressing Multiple
Two Dimensional Multiple
Modified Multiple
Modelling Multiple
Identifying Multiple
Locating Multiple
Diesel Multiple
Modulating Multiple
Novo Multiple
Averaging Multiple
Explore More
Refractory Multiple
Encyclopedia